PT99300A - Processo para a preparacao de composicoes farmaceuticas para a terapia de afeccoes neurologicas em doentes com sida que contem, como ingrediente activo, pelo menos um composto escolhido do grupo que consiste em sais de s-adenosilmetionina, acido 5-metiltetra-hidrofolico e acido 5-formiltetra-hidrofolico e os seus sais - Google Patents

Processo para a preparacao de composicoes farmaceuticas para a terapia de afeccoes neurologicas em doentes com sida que contem, como ingrediente activo, pelo menos um composto escolhido do grupo que consiste em sais de s-adenosilmetionina, acido 5-metiltetra-hidrofolico e acido 5-formiltetra-hidrofolico e os seus sais

Info

Publication number
PT99300A
PT99300A PT99300A PT9930091A PT99300A PT 99300 A PT99300 A PT 99300A PT 99300 A PT99300 A PT 99300A PT 9930091 A PT9930091 A PT 9930091A PT 99300 A PT99300 A PT 99300A
Authority
PT
Portugal
Prior art keywords
acid
pharmaceutical compositions
group
compound selected
methylethrathohydrobenzoic
Prior art date
Application number
PT99300A
Other languages
English (en)
Other versions
PT99300B (pt
Inventor
Pietro La Greca
Original Assignee
Bioresearch Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioresearch Spa filed Critical Bioresearch Spa
Publication of PT99300A publication Critical patent/PT99300A/pt
Publication of PT99300B publication Critical patent/PT99300B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT99300A 1990-10-23 1991-10-22 Processo para a preparacao de composicoes farmaceuticas para a terapia de afeccoes neurologicas em doentes com sida que contem, como ingrediente activo, pelo menos um composto escolhido do grupo que consiste em sais de s-adenosilmetionina, acido 5-metiltetra-hidrofolico e acido 5-formiltetra-hidrofolico e os seus sais PT99300B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT02183390A IT1243859B (it) 1990-10-23 1990-10-23 Composizioni farmaceutiche comprendenti associazioni fra sali di s-adenosil-l-metionina e acido 5-metil (o 5-formil)-tetraidrofolico per la terapia di complicanze neurologiche negli ammalati di aids.

Publications (2)

Publication Number Publication Date
PT99300A true PT99300A (pt) 1992-08-31
PT99300B PT99300B (pt) 1999-04-30

Family

ID=11187495

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99300A PT99300B (pt) 1990-10-23 1991-10-22 Processo para a preparacao de composicoes farmaceuticas para a terapia de afeccoes neurologicas em doentes com sida que contem, como ingrediente activo, pelo menos um composto escolhido do grupo que consiste em sais de s-adenosilmetionina, acido 5-metiltetra-hidrofolico e acido 5-formiltetra-hidrofolico e os seus sais

Country Status (13)

Country Link
US (1) US6093703A (pt)
EP (1) EP0482493B1 (pt)
JP (1) JP3289928B2 (pt)
KR (1) KR100187992B1 (pt)
AT (1) ATE199319T1 (pt)
AU (1) AU645854B2 (pt)
CA (1) CA2053826C (pt)
DE (1) DE69132542T2 (pt)
FI (1) FI914919L (pt)
IT (1) IT1243859B (pt)
NO (1) NO914157D0 (pt)
PT (1) PT99300B (pt)
ZA (1) ZA918355B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
CN1122456C (zh) 1996-01-31 2003-10-01 南亚拉巴马医学科学基金会 含有天然的还原叶酸盐异构体的食品和维生素制品
DE19628514C1 (de) * 1996-07-05 1997-09-25 E Dr Grundmann Kombination von S-Adenosylmethionin und Azidothymidin zur Hemmung der HIV-Replikation
DE19632823C1 (de) * 1996-08-14 1997-11-20 Symbio Herborn Group Gmbh & Co Komplexe zwischen S-(+)-Adenosylmethionin und 3'-Azido-2',3'-didesoxynucleosid als potente Inhibitoren der HIV-Replikation
US7071230B2 (en) 1997-10-02 2006-07-04 Board Of Trustees Of Southern Illinois University Therapeutic use of D-methionine to reduce the toxicity of noise
US8642581B1 (en) 2000-02-11 2014-02-04 Brian D. Halevie-Goldman Compositions and methods for the production of S-adenosylmethionine within the body
IT1317920B1 (it) * 2000-10-20 2003-07-15 Univ Roma S-adenosilmetionina e suoi derivati per il trattamento e laprevenzione della malattia di alzheimer.
US6759395B2 (en) 2000-12-18 2004-07-06 Orchid Chemicals & Pharmaceuticals, Ltd. Soft-gelatin capsule comprising S-adenosylmethionine and a method for producing the same
ITMI20012462A1 (it) * 2001-11-22 2003-05-22 Gnosis Srl Processo per la preparazione di compresse comprendenti s-adenosilmetionina
US20030155045A1 (en) * 2002-02-05 2003-08-21 Williams Peter C. Lubricated low temperature carburized stainless steel parts
JP4956942B2 (ja) * 2004-09-15 2012-06-20 ニプロ株式会社 安定化された注射用水溶液製剤
KR20060051135A (ko) * 2004-09-15 2006-05-19 니프로 가부시키가이샤 안정화된 주사용 수용액 제재
ITMI20050485A1 (it) * 2005-03-23 2006-09-24 Truffini & Regge Farmaceutici Formulazioni granulari rivestite
FR2884421B1 (fr) 2005-04-15 2007-08-10 Virbac Sa Nouveaux moyens de regulation des troubles du comportement chez les animaux de compagnie
WO2006111541A2 (en) * 2005-04-20 2006-10-26 Basf Plant Science Gmbh Expression cassettes for seed-preferential expression in plants
WO2006119589A2 (en) * 2005-05-11 2006-11-16 Ramaekers, Vincent Prevention and therapy of cerebral folate deficiency
ITMI20060629A1 (it) 2006-03-31 2007-10-01 Daniele Giovannone Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
EP2189154A1 (en) * 2008-11-25 2010-05-26 Gnosis S.p.A. Effervescent tablets and mouth-soluble granulates of S-adenosyl methionine and process for the preparation thereof
CN101862333B (zh) * 2009-04-20 2013-07-24 天津药物研究院 左亚叶酸钠稳定的口服制剂及其制备方法
US8329208B2 (en) * 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
WO2012012902A1 (en) * 2010-07-28 2012-02-02 Msi Methylation Sciences Inc. S-adenosylmethionine formulations with enhanced bioavailability
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
US8372451B2 (en) * 2010-02-12 2013-02-12 Alexander Vuckovic, M.D., Llc Compositions and methods for treating depression
ES2540581T3 (es) 2012-10-17 2015-07-10 Methylation Sciences International Srl Composiciones que comprenden S-adenosilmetionina y un éster de ácido gálico
WO2016185413A1 (en) 2015-05-20 2016-11-24 Nestec S.A. Modified release formulations
AU2017397463B2 (en) 2016-11-03 2022-01-06 HedoniaUSA, Inc. Compositions and methods for treating depression
AU2024274445A1 (en) 2023-05-15 2025-11-27 Bonafide Health, Llc Sleep-improving compositions and methods of use
EP4501315A1 (en) 2023-08-04 2025-02-05 Lesaffre et Compagnie Liquid formulations of folates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1227049B (it) * 1988-07-29 1991-03-14 Bioresearch Spa Impiego di derivati adenosinici per la preparazione di composizioni farmaceutiche aventi attivita' immunostimolante.
GB8900812D0 (en) * 1989-01-14 1989-03-08 Univ Manchester Pharmaceutical method and compositions
WO1990009728A1 (en) * 1989-02-09 1990-08-23 Geoffrey James Barton Signal enhancement processor for stereo system
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
DE4005275A1 (de) * 1990-02-20 1991-08-22 Grundmann Ewald Verwendung von s-adenosylmethionin als mittel gegen virale infektionen durch retroviren

Also Published As

Publication number Publication date
IT1243859B (it) 1994-06-28
DE69132542D1 (de) 2001-04-05
ZA918355B (en) 1992-07-29
EP0482493A2 (en) 1992-04-29
EP0482493A3 (en) 1992-09-02
IT9021833A0 (it) 1990-10-23
NO914157D0 (no) 1991-10-23
EP0482493B1 (en) 2001-02-28
PT99300B (pt) 1999-04-30
AU645854B2 (en) 1994-01-27
FI914919A0 (fi) 1991-10-18
ATE199319T1 (de) 2001-03-15
FI914919A7 (fi) 1992-04-24
JPH04264031A (ja) 1992-09-18
JP3289928B2 (ja) 2002-06-10
CA2053826C (en) 2002-12-17
KR100187992B1 (ko) 1999-06-01
IT9021833A1 (it) 1992-04-23
US6093703A (en) 2000-07-25
CA2053826A1 (en) 1992-04-24
AU8670891A (en) 1992-04-30
FI914919L (fi) 1992-04-24
KR920007629A (ko) 1992-05-27
DE69132542T2 (de) 2001-06-21

Similar Documents

Publication Publication Date Title
PT99300A (pt) Processo para a preparacao de composicoes farmaceuticas para a terapia de afeccoes neurologicas em doentes com sida que contem, como ingrediente activo, pelo menos um composto escolhido do grupo que consiste em sais de s-adenosilmetionina, acido 5-metiltetra-hidrofolico e acido 5-formiltetra-hidrofolico e os seus sais
FR2621585B1 (fr) Derives de 4h-benzopyranne-1 one-4 et leurs sels, leurs procedes de fabrication et compositions pharmaceutiques les comprenant en tant qu'ingredients actifs
DK44791A (da) Behandling af beskadiget knoglemarv
IL75851A (en) Pharmaceutical composition comprising xanthine derivatives and o-acetyl-salicylic acid or its pharmacologically tolerated salts and its preparation
ES2071725T3 (es) Diesteres fosfato de acido ascorbico y tocoferilo para la inhibicion de la reaccion de maillard.
BR0213242A (pt) Composto ou um seu sal ou solvato, composto e seus sais de adição de ácido fisiologicamente aceitáveis, composição farmacêutica, método de tratamento de um ou mais distúrbios, uso de um composto, e, processo de preparação de um composto
HU213677B (en) Pharmaceutical compositions for preventing and treating tumor diseases, and process for producing them
SE8406538D0 (sv) Novel derivatives of purine
ATE220321T1 (de) Feste flupirtin enthaltende orale darreichungsformen mit kontrollierter wirkstoffabgabe
BRPI9915480B8 (pt) azalídeos de 13 membros, composições farmacêuticas compreendendo os mesmos, método para sua preparação bem como seus usos.
BR0010257A (pt) Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, método para tratamento ou profilaxia de condições associadas com a inibição da carboxipeptidase u, kits de partes, e, método de tratamento de um paciente sofrendo de ou susceptìvel a uma condição em que a inibição da carboxipeptidase u e um mecanismo antitrombótico diferente são necessários ou desejados
DK98089A (da) Medikament-lipid-systemer med lav toxicitet
GR3019234T3 (en) Stable compositions for parenteral administration and their use
DK0476066T3 (da) Antiviralt præparat indeholdende 3-azido-2,3-dideoxy-5-methylcytidin
DE10299023I1 (de) Antineoplastisch wirkender und den Antineoplastischen effekt Verstaerkender Wirkstoff
FI903692A0 (fi) Salter av n5, n10-metylen-5,6,7,8- tetrahydrofolsyra.
SE8501532L (sv) Nya lekemedelskombinationer med synergistisk verkan och forfarande for deras framstellning
PT99091A (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados da triazina e da pirimidina, como ingredientes activos, destinadas a reverter a resistencia aos agentes anticancerosos e antimalaricos
Jalava et al. Cephalexin levels in serum, synovial fluid and joint tissues after oral administration
GB2122197B (en) Antiviral guanine derivatives
IL92402A0 (en) Pyrimidine nucleoside derivatives,their preparation and pharmaceutical compositions containing them
GB8608893D0 (en) D-nor-7-ergoline derivatives
KR910018026A (ko) α-페닐-α피리딜알칸산 유도체를 함유하는 배뇨장애증상 치료제
KR890001555A (ko) 요산 배설용 조성물
ATE23161T1 (de) 3-deazaguanin-sulfonsaeuresalze.

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19920422

FG3A Patent granted, date of granting

Effective date: 19990120

PC3A Transfer or assignment

Free format text: KNOLL FARMACEUTICI SPA IT

Effective date: 20040422

PD3A Change of proprietorship

Free format text: KNOLL-RAVIZZA FARMACEUTICI S.P.A. IT

Effective date: 20040422

TE3A Change of address (patent)

Free format text: KNOLL FARMACEUTICI S.P.A. IT

Effective date: 20040422

Free format text: KNOLL-RAVIZZA FARMACEUTICI S.P.A. IT

Effective date: 20040422

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20040720